Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $60.4 million.

  • Stoke Therapeutics' Shares Outstanding (Diluted Average) rose 7.20% to $60.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 7.20%. This contributed to the annual value of $54.0 million for FY2024, which is 22.76% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Shares Outstanding (Diluted Average) is $60.4 million, which was up 1.20% from $59.7 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Shares Outstanding (Diluted Average) registered a high of $60.4 million during Q3 2025, and its lowest value of $37.4 million during Q1 2022.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $51.5 million, with a median of $54.0 million in 2024.
  • Data for Stoke Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY increased of 28.44% (in 2025) over the last 5 years.
  • Stoke Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $38.9 million in 2022, then climbed by 13.10% to $44.0 million in 2023, then increased by 22.76% to $54.0 million in 2024, then increased by 7.20% to $60.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $60.4 million for Q3 2025, versus $59.7 million for Q2 2025 and $59.4 million for Q1 2025.